Humana (HUM) shares plunged 5.02% in Thursday's intraday trading session, as several prominent Wall Street analysts lowered their price targets for the health insurance giant. The stock's significant drop comes amid growing concerns about the company's near-term prospects.

Leading financial institutions have adjusted their outlook on Humana. Leerink Partners reduced its price target from $273 to $267, while maintaining a Market Perform rating. Jefferies also trimmed its target, moving from $256 to $253, and kept its Hold rating. Similarly, Piper Sandler lowered its price target to $265 from $272, reiterating a Neutral stance on the stock.

These downgrades reflect a cautious sentiment among analysts regarding Humana's future performance. Despite the reduced price targets, the average rating for Humana remains a Hold, with a mean price target of $288.04 according to FactSet data. The collective actions of these financial firms appear to have triggered a sell-off, contributing to the sharp decline in Humana's stock price during the trading session.